# Soluble guanylate cyclase stimulators

Drug · id `cardio:soluble-guanylate-cyclase-stimulators` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Soluble Guanylate Cyclase Stimulator; Guanylate Cyclase Stimulators; sGC stimulators

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

Soluble guanylate cyclase (sGC) stimulators are medicines that act on soluble guanylate cyclase, an enzyme that the Adempas label calls the receptor for nitric oxide. The US label of Adempas (riociguat) calls it an sGC stimulator indicated for two kinds of pulmonary hypertension in adults, and the US label of Verquvo (vericiguat) calls it an sGC stimulator indicated for chronic heart failure. Both medicines have their own pages. This is the class page.

## Technical summary

Class page. MeSH has no descriptor for the class: an exact-label lookup for the descriptor returned an empty list on 2026-11-18, so the identifiers list is empty. RxClass lists the established pharmacologic class on US drug labels Soluble Guanylate Cyclase Stimulator (EPC) for riociguat and for vericiguat, and the mechanism-of-action class Guanylate Cyclase Stimulators for riociguat (read 2026-11-18); both are filed under this page on that evidence. The Adempas label (NDA204819; effective 2026-08-13) and the Verquvo label (NDA214377; effective 2026-01-21) each use the class name in their first indication sentence. The two labels list different conditions. No trial result, dose or instruction is recorded.

## Connected pages

- Files under this front: Medicines (`cardio:front-medicines`)
- The Adempas label lists chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension as indications: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- The Adempas label lists pulmonary arterial hypertension as an indication: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- The Verquvo label lists chronic heart failure as the indication: Heart failure (`cardio:heart-failure`)
- Has subtype: Riociguat (`cardio:riociguat`)
- Has subtype: Vericiguat (`cardio:vericiguat`)

## Provenance

Content hash: d666ee0a27400a4cffeaadcecd073a866e94ca1c18173e91d423a559495bcb4a
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
